Placental transfer of rosiglitazone in the ex vivo human perfusion model

Heather J. Holmes, Brian M. Casey, Roger E. Bawdon

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: The objective of the study was to determine transplacental passage of rosiglitazone (Avandia) using the ex vivo human placental model. Study design: Perfusion studies were performed on 10 placentas from term, uncomplicated deliveries. Concentrations typical for an 8-mg oral dose (216 to 692 ng/mL) as well as 2- to 3-fold increased concentrations were tested (734 to 1261 ng/mL). Transfer of rosiglitazone was assessed and accumulation was determined using the 14C-antipyrine reference method. Results: The clearance index for low and high concentrations were 0.14 ± 0.04 and 0.20 ± 0.08, suggesting that the drug passes through the placenta at a relatively low rate. Fetal accumulation occurred in only 1 of 5 placentas at 16.4 ng/mL (5%) for the 8-mg dose and in 2 of 5 placentas ranging from 0 to 74 ng/mL (5% to 8%) at higher concentrations. Conclusion: There is minimal transfer and fetal accumulation of rosiglitazone according to the ex vivo human perfusion model.

Original languageEnglish (US)
Pages (from-to)1715-1719
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume195
Issue number6
DOIs
StatePublished - Dec 2006

Fingerprint

rosiglitazone
Placenta
Perfusion
Antipyrine
Pharmaceutical Preparations

Keywords

  • Placental transfer
  • Rosiglitazone

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Placental transfer of rosiglitazone in the ex vivo human perfusion model. / Holmes, Heather J.; Casey, Brian M.; Bawdon, Roger E.

In: American Journal of Obstetrics and Gynecology, Vol. 195, No. 6, 12.2006, p. 1715-1719.

Research output: Contribution to journalArticle

Holmes, Heather J. ; Casey, Brian M. ; Bawdon, Roger E. / Placental transfer of rosiglitazone in the ex vivo human perfusion model. In: American Journal of Obstetrics and Gynecology. 2006 ; Vol. 195, No. 6. pp. 1715-1719.
@article{02547db352e34191aaf9446484187f96,
title = "Placental transfer of rosiglitazone in the ex vivo human perfusion model",
abstract = "Objective: The objective of the study was to determine transplacental passage of rosiglitazone (Avandia) using the ex vivo human placental model. Study design: Perfusion studies were performed on 10 placentas from term, uncomplicated deliveries. Concentrations typical for an 8-mg oral dose (216 to 692 ng/mL) as well as 2- to 3-fold increased concentrations were tested (734 to 1261 ng/mL). Transfer of rosiglitazone was assessed and accumulation was determined using the 14C-antipyrine reference method. Results: The clearance index for low and high concentrations were 0.14 ± 0.04 and 0.20 ± 0.08, suggesting that the drug passes through the placenta at a relatively low rate. Fetal accumulation occurred in only 1 of 5 placentas at 16.4 ng/mL (5{\%}) for the 8-mg dose and in 2 of 5 placentas ranging from 0 to 74 ng/mL (5{\%} to 8{\%}) at higher concentrations. Conclusion: There is minimal transfer and fetal accumulation of rosiglitazone according to the ex vivo human perfusion model.",
keywords = "Placental transfer, Rosiglitazone",
author = "Holmes, {Heather J.} and Casey, {Brian M.} and Bawdon, {Roger E.}",
year = "2006",
month = "12",
doi = "10.1016/j.ajog.2006.03.054",
language = "English (US)",
volume = "195",
pages = "1715--1719",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Placental transfer of rosiglitazone in the ex vivo human perfusion model

AU - Holmes, Heather J.

AU - Casey, Brian M.

AU - Bawdon, Roger E.

PY - 2006/12

Y1 - 2006/12

N2 - Objective: The objective of the study was to determine transplacental passage of rosiglitazone (Avandia) using the ex vivo human placental model. Study design: Perfusion studies were performed on 10 placentas from term, uncomplicated deliveries. Concentrations typical for an 8-mg oral dose (216 to 692 ng/mL) as well as 2- to 3-fold increased concentrations were tested (734 to 1261 ng/mL). Transfer of rosiglitazone was assessed and accumulation was determined using the 14C-antipyrine reference method. Results: The clearance index for low and high concentrations were 0.14 ± 0.04 and 0.20 ± 0.08, suggesting that the drug passes through the placenta at a relatively low rate. Fetal accumulation occurred in only 1 of 5 placentas at 16.4 ng/mL (5%) for the 8-mg dose and in 2 of 5 placentas ranging from 0 to 74 ng/mL (5% to 8%) at higher concentrations. Conclusion: There is minimal transfer and fetal accumulation of rosiglitazone according to the ex vivo human perfusion model.

AB - Objective: The objective of the study was to determine transplacental passage of rosiglitazone (Avandia) using the ex vivo human placental model. Study design: Perfusion studies were performed on 10 placentas from term, uncomplicated deliveries. Concentrations typical for an 8-mg oral dose (216 to 692 ng/mL) as well as 2- to 3-fold increased concentrations were tested (734 to 1261 ng/mL). Transfer of rosiglitazone was assessed and accumulation was determined using the 14C-antipyrine reference method. Results: The clearance index for low and high concentrations were 0.14 ± 0.04 and 0.20 ± 0.08, suggesting that the drug passes through the placenta at a relatively low rate. Fetal accumulation occurred in only 1 of 5 placentas at 16.4 ng/mL (5%) for the 8-mg dose and in 2 of 5 placentas ranging from 0 to 74 ng/mL (5% to 8%) at higher concentrations. Conclusion: There is minimal transfer and fetal accumulation of rosiglitazone according to the ex vivo human perfusion model.

KW - Placental transfer

KW - Rosiglitazone

UR - http://www.scopus.com/inward/record.url?scp=33751252556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751252556&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2006.03.054

DO - 10.1016/j.ajog.2006.03.054

M3 - Article

C2 - 16707076

AN - SCOPUS:33751252556

VL - 195

SP - 1715

EP - 1719

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -